Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

Br J Haematol. 2011 Jul;154(2):284-6. doi: 10.1111/j.1365-2141.2011.08618.x. Epub 2011 Apr 26.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Carboplatin / administration & dosage
  • Disease-Free Survival
  • Etoposide / administration & dosage
  • Hodgkin Disease / drug therapy*
  • Humans
  • Ifosfamide / administration & dosage
  • Pyrazines / administration & dosage
  • Recurrence
  • Treatment Outcome
  • Young Adult

Substances

  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • Etoposide
  • Carboplatin
  • Ifosfamide

Supplementary concepts

  • ICE protocol 3